Analyst Thomas Shrader from BTIG maintained a Buy rating on COMPASS Pathways and keeping the price target at $14.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Shrader has given his Buy rating due to a combination of factors, including a steadily improving regulatory backdrop and the attractive positioning of COMP360 for treatment centers. He highlights that the new CNPV voucher could accelerate the final steps to approval, while recent trial data show COMP360 provides meaningful and durable symptom relief for a broad set of treatment‑resistant patients.
Shrader also points to CMPS’s strong balance sheet, with an extended cash runway into 2028, and the company’s disciplined spending as Phase 3 trials conclude. In his view, COMP360 should be commercially appealing versus existing options like SPRAVATO, potentially offering better economics for centers, and the robustness of the data package makes eventual approval and center adoption highly likely, supporting the unchanged $14 price target.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $29.00 price target.